Search Results - "Mahmmod, Nofel"

Incidence of Interval Colorectal Cancer Among Inflammatory Bowel Disease Patients Undergoing Regular Colonoscopic Surveillance by Mooiweer, Erik, van der Meulen-de Jong, Andrea E, Ponsioen, Cyriel Y, van der Woude, C. Janneke, van Bodegraven, Ad A, Jansen, Jeroen M, Mahmmod, Nofel, Kremer, Willemijn, Siersema, Peter D, Oldenburg, Bas

“…Background & Aims Surveillance is recommended for patients with long-term inflammatory bowel disease because they have an increased risk of colorectal cancer…”
Get full text

Clinical Predictors of Future Nonadherence in Inflammatory Bowel Disease by Severs, Mirjam, Mangen, Marie-Josée J, Fidder, Herma H, van der Valk, Mirthe E, van der Have, Mike, van Bodegraven, Ad A, Clemens, Cees H M, Dijkstra, Gerard, Jansen, Jeroen M, de Jong, Dirk J, Mahmmod, Nofel, van de Meeberg, Paul C, van der Meulen-de Jong, Andrea E, Pierik, Marieke, Ponsioen, Cyriel Y, Romberg-Camps, Marielle J L, Siersema, Peter D, Jharap, Bindia, van der Woude, Janneke C, Zuithoff, Nicolaas P A, Oldenburg, Bas

“…Nonadherence to medical therapy is frequently encountered in patients with inflammatory bowel disease (IBD). We aimed to identify predictors for future…”
Get full text

Anti-tumor necrosis factor therapy in patients with inflammatory bowel disease; comorbidity, not patient age, is a predictor of severe adverse events by Asscher, Vera E. R., van der Vliet, Quirine, van der Aalst, Karen, van der Aalst, Anniek, Brand, Eelco C., van der Meulen-de Jong, Andrea E., Oldenburg, Bas, Pierik, Marieke J., van Tuyl, Bas, Mahmmod, Nofel, Maljaars, P. W. Jeroen, Fidder, Herma H.

“…Purpose To assess safety and effectiveness of anti-tumor necrosis factor (anti-TNF) therapy in IBD patients ≥ 60 years. Methods Ninety IBD patients ≥ 60 years…”
Get full text

Use of Multilocus Variable-Number Tandem-Repeat Analysis for Typing Mycobacterium avium subsp. paratuberculosis by OVERDUIN, Pieter, SCHOULS, Leo, ROHOLL, Paul, VAN DER ZANDEN, Adri, MAHMMOD, Nofel, HERREWEGH, Arnold, VAN SOOLINGEN, Dick

“…Article Usage Stats Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial by de Jong, Marin J, van der Meulen-de Jong, Andrea E, Romberg-Camps, Mariëlle J, Becx, Marco C, Maljaars, Jeroen P, Cilissen, Mia, van Bodegraven, Ad A, Mahmmod, Nofel, Markus, Tineke, Hameeteman, Wim M, Dijkstra, Gerard, Masclee, Ad A, Boonen, Annelies, Winkens, Bjorn, van Tubergen, Astrid, Jonkers, Daisy M, Pierik, Marie J

“…Tight and personalised control of inflammatory bowel disease in a traditional setting is challenging because of the disease complexity, high pressure on…”
Get full text

Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease by Mahmoud, Remi, Schultheiss, Hans-Paul, Louwers, Jonas, van der Kaaij, Michiel, van Hellemondt, Boris, Mahmmod, Nofel, van Boeckel, Petra, Jharap, Bindia, Fidder, Herma, Oldenburg, Bas

“…The benefit of concomitant immunomodulators (thiopurines or methotrexate) in patients with inflammatory bowel disease (IBD) on anti-tumor necrosis factor α…”
Get full text

Cost-effectiveness of Telemedicine-directed Specialized vs Standard Care for Patients With Inflammatory Bowel Diseases in a Randomized Trial by de Jong, Marin J., Boonen, Annelies, van der Meulen-de Jong, Andrea E., Romberg-Camps, Mariëlle J., van Bodegraven, Ad A., Mahmmod, Nofel, Markus, Tineke, Dijkstra, Gerard, Winkens, Bjorn, van Tubergen, Astrid, Masclee, Ad, Jonkers, Daisy M., Pierik, Marie J.

“…Telemedicine can be used to monitor determinants and outcomes of patients with chronic diseases, possibly increasing the quality and value of care…”
Get full text

Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study by van der Valk, Mirthe Emilie, Mangen, Marie-Josée J, Leenders, Max, Dijkstra, Gerard, van Bodegraven, Ad A, Fidder, Herma H, de Jong, Dirk J, Pierik, Marieke, van der Woude, C Janneke, Romberg-Camps, Mariëlle J L, Clemens, Cees H M, Jansen, Jeroen M, Mahmmod, Nofel, van de Meeberg, Paul C, van der Meulen-de Jong, Andrea E, Ponsioen, Cyriel Y, Bolwerk, Clemens J M, Vermeijden, J Reinoud, Siersema, Peter D, van Oijen, Martijn G H, Oldenburg, Bas

“…The introduction of anti tumour necrosis factor-α (anti-TNFα) therapy might impact healthcare expenditures, but there are limited data regarding the costs of…”
Get more information

High Risk of Advanced Colorectal Neoplasia in Patients With Primary Sclerosing Cholangitis Associated With Inflammatory Bowel Disease by Shah, Shailja C., ten Hove, Joren R., Castaneda, Daniel, Palmela, Carolina, Mooiweer, Erik, Colombel, Jean-Frédéric, Harpaz, Noam, Ullman, Thomas A., van Bodegraven, Ad A., Jansen, Jeroen M., Mahmmod, Nofel, van der Meulen-de Jong, Andrea E., Ponsioen, Cyriel Y., van der Woude, Christine J., Oldenburg, Bas, Itzkowitz, Steven H., Torres, Joana

“…Patients with inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC, termed PSC-IBD) are at increased risk for colorectal cancer, but their…”
Get full text

Loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel disease by Schultheiss, Johannes P. D., Mahmoud, Remi, Louwers, Jonas M., Kaaij, Michiel T., Hellemondt, Boris P., Boeckel, Petra G., Mahmmod, Nofel, Jharap, Bindia, Fidder, Herma H., Oldenburg, Bas

“…Summary Background Inflammatory bowel disease (IBD) is often managed with anti‐tumour necrosis factor‐α therapy (anti‐TNFα), but treatment efficacy is…”
Get full text

721: IMMUNOMODULATOR WITHDRAWAL FROM ANTI-TNF THERAPY IS NOT ASSOCIATED WITH LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE by Mahmoud, Remi, Schultheiss, Johannes P., Louwers, Jonas M., Kaaij, Michiel T. van der, Hellemondt, Boris P. van, Mahmmod, Nofel, Boeckel, Petra G. van, Jharap, Bindia, Fidder, Herma H., Oldenburg, Bas

Get full text

Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life by Kanis, Shannon Linda, Modderman, Sanne, Escher, Johanna C, Erler, Nicole, Beukers, Ruud, de Boer, Nanne, Bodelier, Alexander, Depla, Annekatrien C T M, Dijkstra, Gerard, van Dijk, Anne-Baue Ruth Margaretha, Gilissen, Lennard, Hoentjen, Frank, Jansen, Jeroen M, Kuyvenhoven, Johan, Mahmmod, Nofel, Mallant-Hent, Rosalie C, van der Meulen-de Jong, Andrea E, Noruzi, Anahita, Oldenburg, Bas, Oostenbrug, Liekele E, Ter Borg, Pieter C J, Pierik, Marieke, Romberg-Camps, Mariëlle, Thijs, Willem, West, Rachel, de Lima, Alison, van der Woude, C Janneke

“…The aim of this study was to describe the long-term health outcomes of children born to mothers with inflammatory bowel disease (IBD) and to assess the impact…”
Get more information

Su458 LOSS-OF-RESPONSE TO ANTI-TNFα CRITICALLY DEPENDS ON TREATMENT DURATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE by Schultheiss, Johannes P., Mahmoud, Remi, Louwers, Jonas M., van der Kaaij, Michiel T., van Hellemondt, Boris P., van Boeckel, Petra G., Mahmmod, Nofel, Jharap, Bindia, Fidder, Herma H., Oldenburg, Bas

Get full text

Healthy Cotwins Share Gut Microbiome Signatures With Their Inflammatory Bowel Disease Twins and Unrelated Patients by Brand, Eelco C., Klaassen, Marjolein A.Y., Gacesa, Ranko, Vich Vila, Arnau, Ghosh, Hiren, de Zoete, Marcel R., Boomsma, Dorret I., Hoentjen, Frank, Horjus Talabur Horje, Carmen S., van de Meeberg, Paul C., Willemsen, Gonneke, Fu, Jingyuan, Wijmenga, Cisca, van Wijk, Femke, Zhernakova, Alexandra, Oldenburg, Bas, Weersma, Rinse K., Oldenburg, Bas, van Wijk, Femke, Brand, Eelco C., Honkoop, Pieter, Jacobs, Rutger J., Ponsioen, Cyriel Y., de Boer, Nanne K.H., Alderlieste, Yasser A., van Herwaarden, Margot A., van Tuyl, Sebastiaan A.C., Lutgens, Maurice W., Janneke van der Woude, C., Mares, Wout G.M., de Koning, Daan B., Bosman, Joukje H., Vecht, Juda, de Schryver, Anneke M.P., van der Meulen-de Jong, Andrea E., Pierik, Marieke J., Boekema, Paul J., Verburg, Robert J., Jharap, Bindia, Willemsen, Gonneke, Boomsma, Dorret I., Jansen, Jeroen M., Stokkers, Pieter C.F., Hoentjen, Frank, Quispel, Rutger, Horjus Talabur Horje, Carmen S., van de Meeberg, Paul C., Mahmmod, Nofel, West, Rachel L., Willems, Marleen, Minderhoud, Itta M., Fidder, Herma H., van Schaik, Fiona D.M., Hirdes, Meike M.C., Boontje, Nynke A., Müskens, Bart L.M., Weersma, Rinse K., Romberg-Camps, Marielle J.L.

“…It is currently unclear whether reported changes in the gut microbiome are cause or consequence of inflammatory bowel disease (IBD). Therefore, we studied the…”
Get full text

Sex-Related Differences in Patients With Inflammatory Bowel Disease: Results of 2 Prospective Cohort Studies by Severs, Mirjam, Spekhorst, Lieke M, Mangen, Marie-Josée J, Dijkstra, Gerard, Löwenberg, Mark, Hoentjen, Frank, van der Meulen-de Jong, Andrea E, Pierik, Marieke, Ponsioen, Cyriel Y, Bouma, Gerd, van der Woude, Janneke C, van der Valk, Mirthe E, Romberg-Camps, Marielle J L, Clemens, Cees H M, van de Meeberg, Paul, Mahmmod, Nofel, Jansen, Jeroen, Jharap, Bindia, Weersma, Rinse K, Oldenburg, Bas, Festen, Eleonora A M, Fidder, Herma H

“…Abstract Background The understanding of gender differences in inflammatory bowel disease (IBD) patients is an important step towards tailored treatment for…”
Get full text

Therapeutic drug monitoring of methotrexate in patients with Crohn's disease by van de Meeberg, Maartje M, Fidder, Herma H, Oldenburg, Bas, Sundaresan, Janani, Struys, Eduard A, Montazeri, Nahid S M, Mares, Wout G N, Mahmmod, Nofel, van Asseldonk, Dirk P, Lutgens, Maurice W M D, Kuyvenhoven, Johan P, Rietdijk, Svend T, Nissen, Loes H C, Koehestanie, Parweez, de Boer, Nanne K H, de Jonge, Robert, Bouma, Gerd, Bulatović Ćalasan, Maja

“…Therapeutic drug monitoring (TDM) has the potential to improve efficacy and diminish side effects. Measuring methotrexate-polyglutamate (MTX-PG) in…”
Get full text

Tu1498: WITHDRAWAL OF THIOPURINES IN INFLAMMATORY BOWEL DISEASE PATIENTS IN STABLE REMISSION: A PROSPECTIVE, MULTICENTER COHORT STUDY by Savelkoul, Edo, Mahmoud, Remi, Jong, Dirk J. De, Dop, Willemijn A. van, Romkens, Tessa E.H, Nissen, Loes H., Mahmmod, Nofel, Boeckel, Petra G. van, Lutgens, Maurice, Mares, Wout, Epping, Ludger, Minderhoud, Itta M., Jansen, Jeroen M., Gisbertz, Ingrid A., Boekema, Paul, Koning, Daan de, Horje, Carmen S. Horjus Talabur, Jharap, Bindia, Oldenburg, Bas, Hoentjen, Frank

Get full text

Mo1539: ANTI-TNF WITHDRAWAL IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN ENDOSCOPIC REMISSION: A PROSPECTIVE STUDY by Mahmoud, Remi, Savelkoul, Edo, Mares, Wout, Goetgebuer, Rogier, Witteman, Ben, Koning, Daan de, Minderhoud, Itta M., Tuyl, Sebastiaan van, Boeckel, Petra G. van, Mahmmod, Nofel, Lutgens, Maurice, Horje, Carmen S. Horjus Talabur, Romkens, Tessa E.H, Akol-Simsek, Dilek, Jansen, Jeroen M., Colombel, Jean Frederic, Hoentjen, Frank, Jharap, Bindia, Oldenburg, Bas

Get full text

Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up by van der Valk, Mirthe E, Mangen, Marie-Josée J, Severs, Mirjam, van der Have, Mike, Dijkstra, Gerard, van Bodegraven, Ad A, Fidder, Herma H, de Jong, Dirk J, van der Woude, C Janneke, Romberg-Camps, Mariëlle J L, Clemens, Cees H M, Jansen, Jeroen M, van de Meeberg, Paul C, Mahmmod, Nofel, van der Meulen-de Jong, Andrea E, Ponsioen, Cyriel Y, Bolwerk, Clemens, Vermeijden, J Reinoud, Siersema, Peter D, Leenders, Max, Oldenburg, Bas

“…With the increasing use of anti-TNF therapy in inflammatory bowel disease (IBD), a shift of costs has been observed with medication costs replacing…”
Get full text

Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study by Derikx, Lauranne A A P, Lantinga, Marten A, de Jong, Dirk J, van Dop, Willemijn A, Creemers, Rob H, Römkens, Tessa E H, Jansen, Jeroen M, Mahmmod, Nofel, West, Rachel L, Tan, Adriaan C I T L, Bodelier, Alexander G L, Gorter, Moniek H P, Boekema, Paul J, Halet, Eric R C, Horjus, Carmen S, van Dijk, Maarten A, Hirdes, Meike M C, Epping Stippel, Ludger S M, Jharap, Bindia, Lutgens, Maurice W M D, Russel, Maurice G, Gilissen, Lennard P L, Nauta, Sjoukje, van Bodegraven, Adriaan A, Hoentjen, Frank

“…Abstract Background and Aims The COVID-19 risk and disease course in inflammatory bowel disease [IBD] patients remains uncertain. Therefore, we aimed to assess…”
Get full text